Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.69 |
| ▸ | CNR2 | P34972 | 1/20 | 0.69 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844571 | 0.93 | CNR1 (0.79) | CNR1CNR2TP53MAPTSMN1; SMN2 | |
| SCHEMBL844625 | 0.88 | CNR1 (0.57) | CNR1CNR2AGTR2AGTR1 | |
| SCHEMBL845150 | 0.86 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL11071403 | 0.85 | CNR1 (0.49) | CNR1CNR2TP53 | |
| SCHEMBL844333 | 0.84 | CNR1 (0.90) | CNR1CNR2 | |
| SCHEMBL844334 | 0.83 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL844904 | 0.83 | CNR1 (0.72) | CNR1CNR2TP53MAPT | |
| SCHEMBL17694535 | 0.83 | CNR1 (0.79) | CNR1CNR2MAPTSMN1; SMN2 | |
| SCHEMBL17692331 | 0.82 | CNR1 (0.90) | CNR1CNR2MAPTSMN1; SMN2 | |
| SCHEMBL844174 | 0.82 | CNR1 (0.87) | CNR1CNR2TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552015-B2 | Quinazolinone derivatives and their use as CB agonists | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | claimed |
| EP-1472234-B1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | claimed |
| US-20080004296-A1 | Organic Compounds | CHARMAN CHRISTINE | 2008-01-03 | — | — | US | claimed |
| WO-2005123694-A2 | QUINAZOLINONE COMPOUNDS FOR THE TREATMENT OF COUGH | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | claimed |
| US-8552015-B2 | Quinazolinone derivatives and their use as CB agonists | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-1472234-B1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| EP-2319839-A1 | Quinazolinone derivatives and their use as CB agonists | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| US-20080004296-A1 | Organic Compounds | CHARMAN CHRISTINE | 2008-01-03 | — | — | US | disclosed |
| US-20070265285-A1 | Quinazolinone derivatives and their use as CB agonists | NOVARTIS AG (CH) | 2007-11-15 | — | — | US | disclosed |
| WO-2005123694-A2 | QUINAZOLINONE COMPOUNDS FOR THE TREATMENT OF COUGH | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050085493-A1 | Quinazolinone derivatives and their use as cb agonists | BRAIN CHRISTOPHER T (GB) | 2005-04-21 | — | — | US | disclosed |
| EP-1472234-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | Novartis AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066603-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | NOVARTIS AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265285-A1 | Quinazolinone derivatives and their use as CB agonists | CNR1, ADRB1, ADRA1D | CNR1 1/4885CNR2 8/4885AGTR2 358/4885 |
| US-20080004296-A1 | Organic Compounds | OTC, OAT, CHRM1 | CNR1 595/4885CNR2 1208/4885AGTR2 182/4885 |
| US-20050085493-A1 | Quinazolinone derivatives and their use as cb agonists | CNR1, ADRB1, ADRA2B | CNR1 1/4885CNR2 8/4885AGTR2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.